Jardiance

View All

lexicon-inpefa-for-heart-failure-treatment
LEXICON’s INPEFA: Entry of Another Drug for Heart Failure Treatment

Heart failure is a global pandemic that affects at least 26 million people globally and is becoming more common. Heart failure health expenditures are substantial and will rise considerably as the population ages. Despite significant advancements in medicines and prevention, mortality and morbidity remain high, and...

Find More

Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches

J&J's Invokana matches Jardiance's 14% reduction in major CV events There’s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits—and amputation risks—along with it. In a cardiovascular outcomes trial, Johnson & Johnson's Invokana matched up to Eli Lilly and Boehringer...

Find More

Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns

Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics Novartis has been mining a pivotal study of Entresto, its heart-failure med, for more insights ever since it was first published in 2014. Now, a new analysis shows that Entresto beat an older med at reducing blood sugar levels in heart failure...

Find More